Clinical Trials
37 trialsIsa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
UNC Lineberger Comprehensive Cancer Center
TAPUR
American Society of Clinical Oncology
BELAMI
Centre Hospitalier Universitaire de Saint Etienne
POM MM 014
Celgene
IFM2014-04
University Hospital, Lille
CLOVER-WaM
Cellectar Biosciences, Inc.
A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
Pfizer
Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma
University of California, San Diego
A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma
AbbVie
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Thomas Jefferson University
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
US Oncology Research
A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM
Canadian Myeloma Research Group
A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies
GlaxoSmithKline
Precision Medicine for Patients With Identified Actionable Mutations
Wake Forest University Health Sciences
Vaccine Therapy in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE
Canadian Myeloma Research Group
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Novartis
A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment
Hellenic Society of Hematology
A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor
Hellenic Society of Hematology
A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
AbbVie
Study of Immune Response Modifier in the Treatment of Hematologic Malignancies
Masonic Cancer Center, University of Minnesota
A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy
AbbVie
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Amgen
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
Masonic Cancer Center, University of Minnesota
A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers
Hoffmann-La Roche
Multi-day Doses in Prevention of Nausea and Emesis
University of Kansas Medical Center
Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
University of Utah
Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
Valerio Therapeutics
Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
University of Arkansas
Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Cancer
TME Pharma AG
Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma
Janssen-Cilag International NV
Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant
European Organisation for Research and Treatment of Cancer - EORTC
A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma
GlaxoSmithKline
A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies
Hadassah Medical Organization
Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation
Fred Hutchinson Cancer Center
Total Body Irradiation for Bone Marrow Transplants: Collaborative Efforts
National Institutes of Health Clinical Center (CC)